Uterine Cancer Survival Rates Have Improved Despite Higher Mortality Risks
Socioeconomic or racial disparities may contribute to unchanged overall survival among certain patients with metastatic uterine cancer.
Increased Wait Times Observed for Black/Hispanic Patients With Cervical Cancer
Despite all groups completing chemoradiation within 56 days, delays contributed to a nonsignificant difference in length between Black vs White patients.
How a Radiation Oncologist Answers Patient Questions with Research
A lot of James B. Yu’s research begins with something as simple as a question from a patient regarding what aspects of treatment may be most beneficial.
Pelabresib Plus Ruxolitinib Improves Spleen Responses in Myelofibrosis
The combination regimen was well tolerated in JAK inhibitor-naïve myelofibrosis, with instances of thrombocytopenia managed with dose modifications.
Pembrolizumab/Lenvatinib Elicits Meaningful Responses in High-Grade Serous PROC
A phase 2 trial found that pembrolizumab plus lenvatinib elicited an overall response rate of 37.5% that consisted entirely of partial responses in high-grade serous PROC.
Rina-S Elicits Encouraging Antitumor Activity in Advanced Ovarian Cancer
Data show deep responses with rinatabart sesutecan among patients regardless of folate receptor alpha expression level in a phase 1/2 study.
Abemaciclib Plus Hormonal Therapy Shows Promising Efficacy in LGSOC/EEC
The adverse effect profile of abemaciclib plus hormonal therapy was comparable with prior reports of CDK4/6 inhibitors.
Ramucirumab Maintenance Combo Shows Benefit in HER2– Gastric/GEJ Cancer
Phase 3 data support ramucirumab/paclitaxel switch maintenance as a post-induction therapy for patients who are not eligible for immunotherapy.
Selinexor Maintenance Improves PFS in TP53 Wild-Type Endometrial Cancer
The median PFS in patients with pMMR TP53 wild-type endometrial cancer was 39.5 months with selinexor and 4.9 months with placebo.
Orca-T Displays cGVHD-Free Survival Benefit in Hematologic Malignancies
Overall survival outcomes were enhanced with Orca-T vs allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.
There Is Excitement and Advances in SBRT Treatment For RCC
In radiation oncology, renal cancers are experiencing the greatest levels of change and growth, according to James B. Yu.
Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer
Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.
Niraparib/Bevacizumab Maintenance Sustains HRQOL in Advanced Ovarian Cancer
Results from the OVARIO trial found HRQOL maintained with niraparib/bevacizumab maintenance in patients with advanced ovarian cancer.
Puxitatug Samrotecan Exhibits Efficacy in Advanced/Metastatic EC
Puxitatug samrotecan was well tolerated in patients with advanced or metastatic endometrial cancer.
Metformin Plus IUD Well-Tolerated in EIN/Endometrial Cancer
A slightly higher complete response rate was observed with the metformin regimen vs with the levonorgestrel-releasing IUD alone in endometrial cancer.
Cancer Vaccine/Durvalumab Yields Efficacy in HPV+ Cervical Cancer
Results from the phase 2 DURBAC trial showed BVAC-C/durvalumab improved response in HPV+ cervical cancer.
Luveltamab Tazevibulin Elicits Response in Platinum-Resistant Ovarian Cancer, Low/Medium FRα Expression
The REFRαME-O1 trial improved response in patients with FRα–positive platinum-resistant ovarian cancer, including those with low to medium expression when given luveltamab tazevibulin.
Hysteroscopic Resection Safely Preserves Fertility in Endometrial Cancer
No deaths or significant adverse effects were reported in the screened population among those who received hysteroscopic resection for endometrial cancer.
Mirvetuximab Soravtansine Sustains OS Benefit in FRα+ PROC
Mirvetuximab soravtansine additionally showcased PFS, ORR, and DOR benefits over chemotherapy in FRα-positive platinum-resistant ovarian cancer.
Avutometinib/Defactinib Shows Promise in Advanced Mesonephric Gynecologic Cancer
The phase 2 trial is currently accruing additional patients with advanced mesonephric gynecologic cancer for treatment with avutometinib/defactinib.
Pembrolizumab/Olaparib Yields PFS Significance in Advanced Ovarian Cancer
The KEYLYNK-001 trial found improved PFS among patients with advanced ovarian cancer given pembrolizumab/olaparib.
Zimberelimab Combo Elicits Activity in Previously Treated Cervical Cancer
Combining zimberelimab with lenvatinib produced a manageable safety profile among patients with advanced cervical cancer in a phase 2 trial.
Afuresertib/Paclitaxel Shows No Survival Difference vs Paclitaxel in PROC
Although there was no statistical significance in survival data, afuresertib/paclitaxel improved PFS vs paclitaxel in patients with the pAKT biomarker.
Cadonilimab Combo Shows Encouraging Activity in Advanced Endometrial Cancer
Cadonilimab plus lenvatinib appeared to have a manageable safety profile in a phase 2 trial.
Chemoradiation Reduces Short-Term QOL vs Radiation Alone in Cervical Cancer
Despite similar 36-week results, chemoradiation showed a statistically significant difference in QOL scores at 3 and 7 weeks vs radiation therapy alone.
Olaparib Combo Enhances PFS Across pMMR Endometrial Cancer Subgroups
Adding maintenance olaparib to durvalumab/chemotherapy in pMMR endometrial cancer improved PFS among those with detectable ctDNA at baseline.
Pembrolizumab/CCRT Yields Significant Efficacy in Advanced Cervical Cancer
Second interim analysis results from the KEYNOTE-A18 trial show continued efficacy of pembrolizumab/CCRT in those with locally advanced cervical cancer.
ET Shows Favorable Physical Health Decline Data vs Chemo in Breast Cancer
Endocrine therapy as a treatment for breast cancer showed similar long-lasting physical health decline data as what was seen in women who did not have breast cancer.
Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma
Carfilzomib, lenalidomide, and dexamethasone results from the real world continued to show effective responses and a tolerable safety profile.
Investigating the Emergence of Artificial Intelligence on Oncologic Practice
As artificial intelligence has arrived in the oncology field, experts discuss how this new technology can have implications for transforming clinical practice.
